Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series

被引：1

作者：

Pinelli, Domenico ^{[1
]}

Micalef, Andrea ^{[1
,5
]}

Merelli, Barbara ^{[2
]}

Trezzi, Rosangela ^{[3
]}

Amaduzzi, Annalisa ^{[1
]}

Agnesi, Stefano ^{[1
]}

Guizzetti, Michela ^{[1
]}

Camagni, Stefania ^{[1
]}

Fedele, Veronica ^{[1
,5
]}

Colledan, Michele ^{[1
,4
]}

机构：

[1] ASST Papa Giovanni XXIII, Dept Organ Failure & Transplantat, Piazza OMS 1, I-24127 Bergamo, Italy

[2] ASST Papa Giovanni XXIII, Unit Med Oncol, Piazza OMS 1, I-24127 Bergamo, Italy

[3] ASST Papa Giovanni XXIII, Unit Pathol, Piazza OMS 1, I-24127 Bergamo, Italy

[4] Univ Bicocca, Milan, Italy

[5] Univ Milan, Milan, Italy

来源：

CANCER TREATMENT AND RESEARCH COMMUNICATIONS | 2023年 / 37卷

关键词：

Pancreatic cancer; Complete pathological response; Neoadjuvant therapy; Disease recurrence; NEOADJUVANT THERAPY; COMPLETE RESPONSE; CANCER; FOLFIRINOX;

D O I：

10.1016/j.ctarc.2023.100770

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Pancreatic ductal adenocarcinoma (PDAC) becomes a systemic disease from an early stage. Complete surgical resection remains the only validated and potentially curative treatment; disappointingly only 20% of patients present with a resectable tumour. Although a complete pathological regression (pCR) after the preoperative chemotherapy could intuitively lead to better outcomes and prolonged survival some reports highlighted significant rates of recurrence. Cases Presentation: We describe three cases of pCR following preoperative chemotherapy for PDAC. The first two cases received neoadjuvant mFOLFIRINOX and PAX-G scheme for borderline resectable PDAC. Recurrence appeared 9 and 12 months after surgery. Although both patients started adjuvant therapy straight after the diagnosis of recurrence, the disease rapidly progressed and led them to death 12 and 15 months after surgery. The third case was characterized by germline BRCA2 mutation. The patient presented with PDAC of the body, intrapancreatic biliary stenosis and suspected peritoneal metastasis. One year later, after first and second-line chemotherapy, she underwent explorative laparoscopy and total spleno-pancreatectomy without evidence of viable tumour cells in the surgical specimen. At six months she is recurrence-free. Conclusions: Very few reports describe a complete pathological response following preoperative chemotherapy in pancreatic cancer. We observed three cases in the last three years with disappointing oncological results. Further investigations are needed to predict PDAC prognosis in pCR after chemotherapy.

引用

页数：7

共 27 条

[1]

Yamada D., Et al., Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of “pCR” from the prognostic standpoint, Ann. Gastroenterol. Surg., 3, 6, pp. 676-685, (2019)

[2]

Kim S.J., Park J.Y., Hwang H.S., Kang C.M., Complete response of locally advanced left-sided pancreatic cancer after modified FOLFIRINOX chemotherapy followed by conversion surgery: a case report, Ann. Hepatobiliary Pancreat. Surg., 25, 3, pp. 390-394, (2021)

[3]

Santoni M., Rizzo A., Kucharz J., Mollica V., Rosellini M., Marchetti A., Tassinari E., Monteiro F.S.M., Soares A., Molina-Cerrillo J., Grande E., Battelli N., Massari F., Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis, Cancer Immunol. Immunother. CII, 72, 6, pp. 1365-1379, (2023)

[4]

di Federico A., Mosca M., Pagani R., Carloni R., Frega G., de Giglio A., Rizzo A., Ricci D., Tavolari S., di Marco M., Palloni A., Brandi G., Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes, In Cancers, 14, 10, (2022)

[5]

di Federico A., Tateo V., Parisi C., Formica F., Carloni R., Frega G., Rizzo A., Ricci D., di Marco M., Palloni A., Brandi G., Hacking pancreatic cancer: present and future of personalized medicine, In Pharmaceuticals, 14, 7, (2021)

[6]

Varadhachary G.R., Et al., Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy, Ann. Surg. Oncol., 13, 8, pp. 1035-1046, (2006)

[7]

Tempero M.A., Et al., Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology, J. Natl Compreh. Cancer Netw., 15, 8, pp. 1028-1061, (2017)

[8]

Reni M., Et al., Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial, Lancet Gastroenterol. Hepatol., 3, 6, pp. 413-423, (2018)

[9]

de Luca R., Gianotti L., Pedrazzoli P., Brunetti O., Rizzo A., Sandini M., Paiella S., Pecorelli N., Pugliese L., Pietrabissa A., Zerbi A., Salvia R., Boggi U., Casirati A., Falconi M., Caccialanza R., Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS® and neoadjuvant treatment, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol., 49, 3, pp. 542-549, (2023)

[10]

Macedo F.I., Et al., Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer, Ann. Surg., 270, 3, pp. 400-413, (2019)

← 1 2 3 →